Joana Ramalho

Joana Ramalho

Auto-generated profile, based on publicly available information

Joana Ramalho

Department Physical and Rehabilitation, Entre Douro e Vouga Hospital Centre, Portugal

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
JRJ. Ramalho
J. Ramalho
RSRichard C. Semelka
Richard C. Semelka
MRMiguel Ramalho
Miguel Ramalho
RNR. H. Nunes
R. H. Nunes
MAM. AlObaidy
M. AlObaidy
MCM. Castillo
M. Castillo
SUMMARY: In current practice, gadolinium-based contrast agents have been considered safe when used at clinically recommended doses in patients without severe renal insufficiency. The causal relationship between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with renal insufficiency resulted in new policies regarding the administration of these agents. After an effective screening of patients with renal disease by performing either unenhanced or reduced-dose-enhanced studies in these patients and by using the most stable contrast agents, nephrogenic systemic fibrosis has been largely eliminated since 2009. Evidence of in vivo gadolinium deposition in bone tissue in patients with normal renal function is well-established, but recent literature showing that gadolinium might also deposit in the brain in patients with intact blood-brain barriers caught many individuals in the imaging community by surprise. The purpose of this review was to summarize the literature on gadolinium-based contrast agents, tying together information on agent stability and animal and human studies, and to emphasize that low-stability agents are the ones most often associated with brain deposition.

1 January 2010 in World Journal of Radiology
Verified
Journal Article
Open access
SPSasitorn Petcharunpaisan
Sasitorn Petcharunpaisan
JRJoana Ramalho
Joana Ramalho
MCMauricio Castillo
Mauricio Castillo
Arterial spin labeling in neuroimaging

1 December 2016 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
RSRichard C. Semelka
Richard C. Semelka
JRJoana Ramalho
Joana Ramalho
AVAmi Vakharia
Ami Vakharia
MAMamdoh AlObaidy
Mamdoh AlObaidy
LBLauren M. Burke
Lauren M. Burke
MRMiguel Ramalho
Miguel Ramalho

1 December 2016 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
JRJoana Ramalho
Joana Ramalho
MRMiguel Ramalho
Miguel Ramalho
MJMichael Jay
Michael Jay
LBLauren M. Burke
Lauren M. Burke
RSRichard C. Semelka
Richard C. Semelka

1 November 2017 in Magnetic Resonance Imaging Clinics of North America
Verified
Journal Article
Closed access
JRJoana Ramalho
Joana Ramalho
MRMiguel Ramalho
Miguel Ramalho

1 December 2022 in Journal of Neuroimaging
Verified
Journal Article
Open access
DKDanila Kuroedov
Danila Kuroedov
BCBruno Cunha
Bruno Cunha
JPJaime Pamplona
Jaime Pamplona
MCMauricio Castillo
Mauricio Castillo
JRJoana Ramalho
Joana Ramalho
Cavernous malformations (CMs) are benign vascular malformations that maybe seen anywhere in the central nervous system. They are dynamic lesions, growing or shrinking over time and only rarely remaining stable. Size varies from a few millimeters to a few centimeters. CMs can be sporadic or familial, and while most of them are congenital, de novo and acquired lesions may also be seen. Etiology is still unknown. A genetic molecular mechanism has been proposed since a cerebral cavernous malformation gene loss of function was found in both familial and sporadic lesions. Additionally, recent studies suggest that formation of CMs in humans may be associated with a distinctive bacterial gut composition (microbioma). Imaging is fairly typical but may vary according to age, location, and etiology. Follow‐up is not well established because CMs patients have a highly unpredictable clinical course. Angiogenic and inflammatory mechanisms have been implicated in disease activity, as well as lesional hyperpermeability and iron deposition. Imaging and serum biomarkers of these mechanisms are under current investigation. Treatment options, including surgery or radiosurgery, are not well defined and are dependent upon multiple factors, including clinical presentation, lesion location, number of hemorrhagic events, and medical comorbidities. Our purpose is to review the imaging features of CMs based on their size, location, and etiology, as well as their differential diagnosis and best imaging approach. New insights in etiology will be briefly considered. Follow‐up strategies, including serum and imaging biomarkers, and treatment options will also be discussed.